<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908011</url>
  </required_header>
  <id_info>
    <org_study_id>H08-00287</org_study_id>
    <nct_id>NCT00908011</nct_id>
  </id_info>
  <brief_title>Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets</brief_title>
  <official_title>A Prospective, Randomized Study to Determine the Effect of Ezetimibe in Addition to Rosuvastatin on Lipids in Participants With the Hypercholesterolemia Associated With HIV Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Frosst-Schering Pharma, G.P.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves comparing the effectiveness of treatments in HIV positive patients who
      may be predisposed to heart attack or stroke. The investigators will evaluate the
      effectiveness of two drugs, often prescribed by doctors to these patients, at lowering
      cholesterol and thereby making the patient less them less vulnerable to suffering a heart
      attack or stroke. The investigators believe that the addition of a second drug, from a
      different class of cholesterol lowering medications, will improve the outcome of the
      patients by lowering cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to determine whether HIV positive patients who have suboptimal lipids
      and/or are not reaching specified lipid targets will benefit from the addition of a second
      lipid lowering drug (ezetimibe) to existing lipid lowering therapy with a statin
      (specifically rosuvastatin) versus increasing the dose of the ongoing statin in terms of
      improvements in serum lipid parameters namely total cholesterol, LDL, HDL, triglycerides and
      apolipoprotein B100 (apoB), apolipoprotein A1 (apoA1), apoB/apoA1 ratio.

      The target population will be HIV+ patients with hypercholesterolemia due to highly active
      antiretroviral therapy, the study will have a randomized, parallel design. Sample size will
      be 50 patients already taking 10 mg of rosuvastatin who are not reaching lipid targets to
      receive either an increased dose of rosuvastatin (20mg) or to receive 10mg ezetimibe in
      addition to their ongoing rosuvastatin therapy. There will be 25 patients randomized to each
      group.

      At baseline serum samples will be obtained and tested for serum triglycerides, total
      cholesterol, HDL, total cholesterol:HDL ratio, apoB, apoA1, apoB/apoA1 ratio, liver
      transaminases (AST and ALT), CK, thyroid stimulating hormone, creatinine and fasting blood
      glucose.

      After 12 weeks of therapy serum samples will once again be obtained and tested for serum
      triglycerides, total cholesterol, HDL, total cholesterol:HDL ratio, apolipoprotein B100,
      liver transaminases (AST and ALT), CK, thyroid stimulating hormone, creatinine and fasting
      blood glucose.

      The primary hypothesis is that the combination of rosuvastatin and ezetimibe will lower
      serum apolipoprotein B100/apolipoprotein A1 ratio more so than an increased dose of
      rosuvastatin alone, in participants with mixed dyslipidemia associated with HIV therapy.

      Secondarily we believe the combination of rosuvastatin and ezetimibe will lower the
      concentrations of serum cholesterol, LDL-cholesterol, triglycerides, apolipoprotein B100 and
      C-reactive protein more so than an increased dose of rosuvastatin alone, and that there will
      be no increase in side effects when administered to participants with mixed dyslipidemia
      associated with HIV therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.</measure>
    <time_frame>3 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B, Percent and Absolute Change Total Cholesterol, LDL, HDL, Triglycerides, Apolipoprotein A1, apolipoproteinB/apoliporoteinA1 Ratio and C-reactive Protein</measure>
    <time_frame>3 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety Parameters, Specifically Incidence of Complications as Measured by an Increase in AST &amp;/or ALT ≥3-fold ULN &amp; a CK ≥10-fold ULN</measure>
    <time_frame>3 months from baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increased dose of rosuvastatin to 20mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Ezetrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin (standard care)</intervention_name>
    <description>Increased dose of rosuvastatin to 20mg/day</description>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive

          -  currently taking 10mg of rosuvastatin

          -  recent (within three months) fasting lipid profile in which the serum total
             cholesterol to HDL ratio is &gt;5.0

        Exclusion Criteria:

          -  Previous adverse reaction to ezetimibe

          -  taken ezetimibe within 30 days of starting the study

          -  history of vascular disease

          -  allergic reaction or muscle problems while taking any statin

          -  currently taking other lipid lowering medications (i.e. a fibrates or cholestyramine)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Bondy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital HIV Immunodeficiency/Metabolic Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>May 21, 2009</firstreceived_date>
  <firstreceived_results_date>November 30, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>HIV</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Statin</keyword>
  <keyword>Apolipoprotein B100/Apolipoprotein A1 ratio</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe</title>
          <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
Ezetimibe: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Increased dose of rosuvastatin to 20mg/day
Rosuvastatin (standard care): Increased dose of rosuvastatin to 20mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe</title>
          <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
Ezetimibe: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Increased dose of rosuvastatin to 20mg/day
Rosuvastatin (standard care): Increased dose of rosuvastatin to 20mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.5" spread="7.4"/>
                <measurement group_id="B2" value="57.0" spread="9.9"/>
                <measurement group_id="B3" value="57" spread="8.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.</title>
        <time_frame>3 months from baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
Ezetimibe: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Increased dose of rosuvastatin to 20mg/day
Rosuvastatin (standard care): Increased dose of rosuvastatin to 20mg/day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.</title>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" spread="0.22"/>
                  <measurement group_id="O2" value="0.89" spread="0.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B, Percent and Absolute Change Total Cholesterol, LDL, HDL, Triglycerides, Apolipoprotein A1, apolipoproteinB/apoliporoteinA1 Ratio and C-reactive Protein</title>
        <time_frame>3 months from baseline</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Safety Parameters, Specifically Incidence of Complications as Measured by an Increase in AST &amp;/or ALT ≥3-fold ULN &amp; a CK ≥10-fold ULN</title>
        <time_frame>3 months from baseline</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe</title>
          <description>10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
Ezetimibe: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Increased dose of rosuvastatin to 20mg/day
Rosuvastatin (standard care): Increased dose of rosuvastatin to 20mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Greg Bondy</name_or_title>
      <organization>St. Paul's Hospital/University of B.C.</organization>
      <phone>604-806-8192</phone>
      <email>gbondy@providencehealth.bc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
